Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xtandi with EBRT for intermediate risk prostate cancer
NCT02028988Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Started Feb 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02028988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028988.